Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multi-Stakeholder Approach Helped Push SPC Waiver Up The EU Agenda, Says Medicines For Europe

This article was originally published in SRA

Executive Summary

Medicines for Europe, the association that represents companies marketing generics, biosimilars and 'value-added' medicines, has called on its members to press the European Commission to introduce a manufacturing waiver for drugs still protected by a supplementary protection certificate (SPC) 'as soon as possible.'

Advertisement

Related Content

EC To Consult On Ways To Boost Generics & Biosimilars Industry, Introduce EU-wide SPC
Advertisement
UsernamePublicRestriction

Register

PS118696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel